Evidence map›Paper›PMID 32449003›Full record

Trial reportJournal of cancer research and clinical oncology2020

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).

A Kurreck, M Geissler, U M Martens, J Riera-Knorrenschild, J Greeve, A Florschütz, S Wessendorf, T Ettrich, S Kanzler, D Nörenberg and 10 more

Open access · hybridAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  3. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  4. Article
  5. The potential of monoclonal antibodies for colorectal cancer therapy.Medical oncology (Northwood, London, England) · 2023
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 1 country.

A KurreckDepartment of Hematology, Oncology, and Tumor Immunology (CVK/CCM), Charité University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
M GeisslerKlinikum Esslingen, Esslingen, Germany.
U M MartensKlinik für Innere Medizin III, SLK-Kliniken Heilbronn, Heilbronn, Germany.
J Riera-KnorrenschildUniversitätsklinik Marburg, Marburg, Germany.
J GreeveSt. Vincenz-Krankenhaus Paderborn, Paderborn, Germany.
A FlorschützStadtisches Klinikum Dessau, Dessau, Germany.
S WessendorfKlinikum Esslingen, Esslingen, Germany.
T EttrichUniversitätsklinikum Ulm, Ulm, Germany.
S KanzlerLeopoldina Krankenhaus, Schweinfurt, Germany.
D NörenbergMedical Faculty Mannheim, Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany.
M SeidenstickerKlinik Und Poliklinik für Radiologie, LMU Klinikum, München, Germany.
S HeldClinAssess, Leverkusen, Germany.
P Buechner-SteudelUniversitätsklinikum Halle (Saale), Halle, Germany.
J AtzpodienFranziskus-Hospital Harderberg, Georgsmarienhütte, Germany.
V HeinemannDepartment of Medicine III and Comprehensive Cancer Center, University Hospital Munich (LMU), Munich, Germany.
S StintzingDepartment of Hematology, Oncology, and Tumor Immunology (CVK/CCM), Charité University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
T SeufferleinUniversitätsklinikum Ulm, Ulm, Germany.
A TannapfelInstitute of Pathology, Ruhr-University Bochum, Bochum, Germany.
A C Reinacher-SchickDepartment of Hematology, Oncology and Palliative Care, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
D P ModestDepartment of Hematology, Oncology, and Tumor Immunology (CVK/CCM), Charité University Medicine Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. dominik.modest@charite.de.ORCID http://orcid.org/0000-0002-6853-0599
Charité - Universitätsmedizin Berlin · DEKlinikum Esslingen · DEUniversity Hospital Ulm · DEBrüderkrankenhaus St. Josef Paderborn · DEClinAssess (Germany) · DEGerman Cancer Research Center · DEHeidelberg University · DELeopoldina Krankenhaus Schweinfurt · DELMU Klinikum · DERuhr University Bochum · DESLK-Kliniken Heilbronn · DEStädtisches Klinikum Dessau · DESt. Franziskus Hospital · DESt. Josef-Hospital · DEUniversity Hospital in Halle · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn mCRC, disease dynamics may play a critical role in the understanding of long-term outcome. We evaluated depth of response (DpR), time to DpR, and post-DpR survival as relevant endpoints.

methodsWe analyzed DpR by central review of computer tomography images (change from baseline to smallest tumor diameter), early tumor shrinkage (≥ 20% reduction in tumor diameter at first reassessment), time to DpR (study randomization to DpR-image), post-DpR progression-free survival (pPFS = DpR-image to tumor progression or death), and post-DpR overall survival (pOS = DpR-image to death) with special focus on BRAF status in 66 patients and primary tumor site in 86 patients treated within the VOLFI-trial, respectively.

resultsBRAF wild-type (BRAF-WT) compared to BRAF mutant (BRAF-MT) patients had greater DpR (- 57.6% vs. - 40.8%, p = 0.013) with a comparable time to DpR [4.0 (95% CI 3.1-4.4) vs. 3.9 (95% CI 2.5-5.5) months; p = 0.8852]. pPFS was 6.5 (95% CI 4.9-8.0) versus 2.6 (95% CI 1.2-4.0) months in favor of BRAF-WT patients (HR 0.24 (95% CI 0.11-0.53); p < 0.001). This transferred into a significant difference in pOS [33.6 (95% CI 26.0-41.3) vs. 5.4 (95% CI 5.0-5.9) months; HR 0.27 (95% CI 0.13-0.55); p < 0.001]. Similar observations were made for patients stratified for primary tumor site.

conclusionsBRAF-MT patients derive a less profound treatment response compared to BRAF-WT patients. The difference in outcome according to BRAF status is evident after achievement of DpR with BRAF-MT patients hardly deriving any further disease control beyond DpR. Our observations hint towards an aggressive tumor evolution in BRAF-MT tumors, which may already be molecularly detectable at the time of DpR.

Indexed as

MutationAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCamptothecinColorectal NeoplasmsDisease ProgressionFemaleFluorouracilHumansLeucovorinMaleMiddle AgedNeoplasm MetastasisOrganoplatinum CompoundsPanitumumabBRAF protein, humanCamptothecinFluorouracilLeucovorinOrganoplatinum CompoundsPanitumumabProto-Oncogene Proteins B-rafras ProteinsBRAFCombination chemotherapyDepth of responseDisease dynamicsEarly tumor shrinkageMetastatic colorectal cancerPrimary tumor site

Identifiers

PMID32449003
PMCPMC7467910
OpenAlexW3028147486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.